Cancer Research · 2010 · 73 citations · 20 references
MedicineMolecular BiologyOncologyCancer GeneticsCarcinogenesisMolecular OncologyCancer GenomicsGrowth Factor Receptor OncogenesMolecular Classification Of TumorsNext-generation Sequencing In OncologyOncogene MutationsChronic Lymphocytic Leukemia TherapyChronic Myelomonocytic LeukemiaMet InhibitorsOncogenic Driver MutationsOncogenic TransformationPassenger MutationsSequence Variant CurationVariant Interpretation In Oncology
High-throughput sequencing promises to accelerate the discovery of sequence variants, but distinguishing oncogenic mutations from irrelevant "passenger" mutations remains a major challenge. Here we present an analysis of two sequence variants of the MET receptor (hepatocyte growth factor receptor) R970C and T992I (also designated R988C and T1010I). Previous reports indicated that these sequence variants are transforming and contribute to oncogenesis. We screened patients with chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), colorectal cancer, endometrial cancer, thyroid cancer, or melanoma, as well as individuals without cancer, and found these variants at low frequencies in most cohorts, including normal individuals. No evidence of increased phosphorylation or transformative capacity by either sequence variant was found. Because small-molecule inhibitors for MET are currently in development, it will be important to distinguish between oncogenic sequence variants and rare single-nucleotide polymorphisms to avoid the use of unnecessary, and potentially toxic, cancer therapy agents.
20
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text
Medicine, Hematology, Oncology +13